Cited by 578Berberine and alkaloids researchNatural Antidiabetic Agents StudiesMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine

Zhang, Yifei, Li, Xiaoying, Zou, Dajin, Liu, Wei, Yang, Jialin, Zhu, Na, Huo, Li, Wang, Miao, Hong, Jie, Wu, Peihong, Ren, Guoguang, Ning, Guang·2008·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2007-2404

Open this paper in CoChat — free account

Abstract

Context: Berberine, a natural plant alkaloid, is usually used as an antibiotic drug. The potential glucose-lowering effect of berberine was noted when it was used for diarrhea in diabetic patients. In vitro and in vivo studies have then showed its effects on hyperglycemia and dyslipidemia. Objective: The objective of the study was to evaluate the efficacy and safety of berberine in the treatment of type 2 diabetic patients with dyslipidemia. Design: One hundred sixteen patients with type 2 diabetes and dyslipidemia were randomly allocated to receive berberine (1.0 g daily) and the placebo for 3 months. The primary outcomes were changes in plasma glucose and serum lipid concentrations. Glucose disposal rate (GDR) was measured using a hyperinsulinemic euglycemic clamp to assess insulin sensitivity. Results: In the berberine group, fasting and postload plasma glucose decreased from 7.0 ± 0.8 to 5.6 ± 0.9 and from 12.0 ± 2.7 to 8.9 ± 2.8 mm/liter, HbA1c from 7.5 ± 1.0% to 6.6 ± 0.7%, triglyceride from 2.51 ± 2.04 to 1.61 ± 1.10 mm/liter, total cholesterol from 5.31 ± 0.98 to 4.35 ± 0.96 mm/liter, and low-density lipoprotein-cholesterol from 3.23 ± 0.81 to 2.55 ± 0.77 mm/liter, with all parameters differing from placebo significantly (P < 0.0001, P < 0.0001, P < 0.0001, P = 0.001, P < 0.0001, and P <0.0001, respectively). The glucose disposal rate was increased after berberine treatment (P = 0.037), although no significant change was found between berberine and placebo groups (P = 0.063). Mild to moderate constipation was observed in five participants in the berberine group. Conclusions: Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia.

Integrity signals

Registry

Crossref · 10.1210/jc.2007-2404

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Risks for All-Cause Mortality, Cardiovascular Disease, and Diabetes Associated With the Metabolic Syndrome
Ford, E. S. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1769 · Cited by 1,718
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States
Lee, Y. S., Kim, W. S., Kim, K. H., Yoon, M. J., Cho, H. J., Shen, Y., Ye, J.-M., Lee, C. H., Oh, W. K., Kim, C. T., et al. (2006) · Diabetes · doi:10.2337/db06-0006 · Cited by 1,054
The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes
Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1108 · Cited by 568
Berberine improves glucose metabolism through induction of glycolysis
Yin, J., Gao, Z., Liu, D., Liu, Z., & Ye, J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00211.2007 · Cited by 418
Pharmacokinetics of Berberine and Its Main Metabolites in Conventional and Pseudo Germ-Free Rats Determined by Liquid Chromatography/Ion Trap Mass Spectrometry
Zuo, F., Nakamura, N., Akao, T., & Hattori, M. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011361 · Cited by 284
Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion.
Leng, S.-H., Lu, F., & Xu, L. (2004) · PubMed · Cited by 237

Flagged first, then by citations

Show all 23 references

Research works printed but not linked: 3

Ni, 1988, Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research [article in Chinese]., Zhong Xi Yi Jie He Za Zhi, 8, 711
Xie, 2005, The clinical efficacy of berberine in treatment of type 2 diabetes mellitus [article in Chinese]., Chin J Clin Healthcare, 8, 402
Wei, 2004, Clinical study on improvement of type 2 diabetes mellitus complicated with fatty liver treatment by berberine [article in Chinese], Zhong Xi Yi Jie He Ganbing Za Zhi, 14, 334

Sorted by citations

Items 201–300 of 578

Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results
Cicero, A. F. G., & Ertek, S. (2009) · Clinical Lipidology · doi:10.2217/clp.09.41 · Cited by 48
Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes
Zhou, L., Wang, X., Yang, Y., Wu, L., Li, F., Zhang, R., Yuan, G., Wang, N., Chen, M., & Ning, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.10.001 · Cited by 49
“hyperglycemia [11,12].”
Self-citation
The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials
Asbaghi, O., Ghanbari, N., shekari, M., Reiner, Ž., Amirani, E., Hallajzadeh, J., Mirsafaei, L., & Asemi, Z. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.04.010 · Cited by 47
Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor
Wang, Y., Wang, Y., Zhang, H., Kong, W., Li, Y., Liu, F., Gao, R., Liu, T., Jiang, J., & Song, D. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.059 · Cited by 47
Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway
Li, C. H., Tang, S. C., Wong, C. H., Wang, Y., Jiang, J., & Chen, Y. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.035 · Cited by 45
Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers
Solnier, J., Zhang, Y., Kuo, Y., Du, M., Roh, K., Gahler, R., Wood, S., & Chang, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112567 · Cited by 47
Self-citation
Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients
Chao, M., Zou, D., Zhang, Y., Chen, Y., Wang, M., Wu, H. Y., Ning, G., & Wang, W. (2009) · Endocrine · doi:10.1007/s12020-009-9222-y · Cited by 46
“Recently, a multicentre, double-blind, placebo-controlled clinical trial was accomplished to evaluate the efficacy of berberine in the treatment of T2D with dislipdemia in our clinical research center [13].”
BackgroundSelf-citation
Polycystic ovary syndrome management: a review of the possible amazing role of berberine
Rondanelli, M., Infantino, V., Riva, A., Petrangolini, G., Faliva, M. A., Peroni, G., Naso, M., Nichetti, M., Spadaccini, D., Gasparri, C., et al. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05450-4 · Cited by 46
Enhancement by sodium caprate and sodium deoxycholate of the gastrointestinal absorption of berberine chloride in rats
Fan, D., Wu, X., Dong, W., Sun, W., Li, J., & Tang, X. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.723219 · Cited by 47
Addressing the preventive and therapeutic perspective of berberine against diabetes
Shrivastava, S., Sharma, A., Saxena, N. V., Bhamra, R., & Kumar, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21233 · Cited by 50
“Zhang et al. (2008) verified in a clinical study that oral administration of berbeine at a dose of 1.0 g per day for 3 months is efficacious and safe in the treatment of T2DM and dyslipidemia [139].”
BackgroundInfluential
Renoprotective effects of berberine and its potential effect on the expression of β‐arrestins and intercellular adhesion molecule‐1 and vascular cell adhesion molecule‐1 in streptozocin‐diabetic nephropathy rats
Tang, L., Ni, W., Cai, M., Ding, H., Liu, S., & Shan-tang, Z. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12349 · Cited by 46
“Furthermore, BBR has been reported to improve that ratio of anti-inflammatory to proinflammatory cytokines, such as IL-10: IL-1α, IL-10: IL-6, and IL-10:TNF-α, in diabetic kidney.(32) In addition, BBR has been reported to ameliorate the hemodynamic abnormalities in DN patients.”
Background
Berberine Alleviates Oxidative Stress in Islets of Diabetic Mice by Inhibiting miR‐106b Expression and Up‐Regulating SIRT1
Chen, D., & Yang, K. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26089 · Cited by 45
“Some investigators indicate that BBR also exertes beneficial effects on the treatment of diabetes clinically [Zhang et al., 2013].”
Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
Liu, X., Wang, L., Tan, S., Chen, Z., Wu, B., & Wu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.814871 · Cited by 45
Berberine Attenuates Doxorubicin-Induced Cardiotoxicity in Mice
Zhao, X., Zhang, J., Tong, N., Liao, X., Wang, E., Li, Z., Luo, Y., & Zuo, H. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900514 · Cited by 44
A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention
Bellavite, P., Fazio, S., & Affuso, F. (2023) · Molecules · doi:10.3390/molecules28114491 · Cited by 46
“These results were also associated with a slight reduction in postprandial insulin and body weight [49].”
Result
Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe() mice
Ma, X., Zhang, T., Luo, Z., Li, X., Lin, M., Li, R. P., Du, P., Yu, X.-Y., Ma, C., Yan, P., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.03.005 · Cited by 44
Self-citation
Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs
Li, D., Yu, P., Xiao, W., Wang, Z., & Zhao, L.-G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200908165913 · Cited by 44
Berberine Relieves Metabolic Syndrome in Mice by Inhibiting Liver Inflammation Caused by a High-Fat Diet and Potential Association With Gut Microbiota
Li, J., Li, J., Ni, J., Zhang, C., Jia, J., Wu, G., Sun, H., & Wang, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.752512 · Cited by 46
Chinese Herbal Medicine for Obesity: A Randomized, Double-Blinded, Multicenter, Prospective Trial
Zhou, Q., Chang, B., Chen, X., Zhou, S., Zhong, Z., Zhang, L., Sun, X., Zhou, Y., Xie, W., Liu, H., et al. (2014) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x14500840 · Cited by 43
Medicinal Plants and Phytochemicals Regulating Insulin Resistance and Glucose Homeostasis in Type 2 Diabetic Patients: A Clinical Review
Mahdavi, A., Bagherniya, M., Mirenayat, M. S., Atkin, S. L., & Sahebkar, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-64872-5_13 · Cited by 44
Modulations of cytochrome P450 expression in diabetic mice by berberine
Chatuphonprasert, W., Nemoto, N., Sakuma, T., & Jarukamjorn, K. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.01.006 · Cited by 44
Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy
Calvaruso, M., Pucci, G., Musso, R., Bravatà, V., Cammarata, F. P., Russo, G. I., Forte, G. I., & Minafra, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215267 · Cited by 42
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review
Shinjyo, N., Parkinson, J. R. C., Bell, J. D., Katsuno, T., & Bligh, S. W. A. (2020) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2020.01.004 · Cited by 43
“cholesterol, triglycerides and low-density lipoprotein cholesterol (LDL-C) in T2DM patients [22,23].”
Background
The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches
Habtemariam, S. (2020) · Biomedicines · doi:10.3390/biomedicines8040090 · Cited by 42
“Its antidiabetic [15–17], antiobesity and anti-hyperlipidaemic [16,18] effects have also been well established.”
Background
Enhancement of native fluorescence intensity of berberine by (2-hydroxypropyl)-β-cyclodextrin in capillary electrophoresis coupled by laser-induced fluorescence detection: Application to quality control of medicinal plants
Uzaşçı, S., & Erim, F. B. (2014) · Journal of Chromatography A · doi:10.1016/j.chroma.2014.02.068 · Cited by 41
Synthesis of disaccharide modified berberine derivatives and their anti-diabetic investigation in zebrafish using a fluorescence-based technology
Wang, L., Kong, H., Jin, M., Li, X., Stoika, R. S., Lin, H., & Liu, K. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob00327a · Cited by 39
Self-citation
Berberine Reduces Leukocyte Adhesion to Lps-Stimulated Endothelial Cells and Vcam-1 Expression Both In Vivo and In Vitro
Wu, Y., Chuang, S.-Y., Hong, W.-C., Lai, Y., Chang, G.-J., & Pang, J. S. (2012) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201202500320 · Cited by 40
“Berberine, a natural compound isolated from Chinese medicinal herbs such as Cortexphellodendri and Rhizoma coptidis, possesses significant antiinflammatory effects and has been used clinically to treat chronic inflammation-associated diseases such as diabetes (1, 2), hypertension (3, 4) and dyslipidemia (5-7).”
Background
Berberine Inhibits Proliferative Ability of Breast Cancer Cells by Reducing Metadherin
Sun, Y., Wang, W., & Tong, Y. (2019) · Medical Science Monitor · doi:10.12659/msm.914486 · Cited by 40
“Berberine has been demonstrated to contain a widely pharmacological effect, including antibacterial infection [5], anti-inflammatory action [6], and anti-hyperglycemia [7].”
Background
Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation
Yi, Y., Wang, G., Zhang, W., Yu, S., Fei, J., An, T., Yi, J., Li, F., Huang, T., Yang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55768-9 · Cited by 45
“S11a, berberine, a clinically approved drug used to treat diarrhea and diabetes 41 , remarkably inhibited MT-CO2 expression in Ras-activated A549 and H1299 cells, concomitant with reduced GLS1 expression in a dose-dependent manner.”
Self-citation
Progress in diabetes research in China
Ning, G., Hong, J., Bi, Y., Gu, W., Zhang, Y., Zhang, Z., HUANG, Y., Wang, W., & Xiaoying, L. I. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00037.x · Cited by 39
Self-citation
Novel nutraceutic therapies for the treatment of metabolic syndrome
Martínez‐Abundis, E., Villar, M. M.-D., Pérez-Rubio, K. G., Zúñiga, L. Y., Cortez-Navarrete, M., Ramírez-Rodríguez, A. M., & González-Ortı́z, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i7.142 · Cited by 39
Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation.
Hu, X., Zhang, Y., Xue, Y., Zhang, Z., & Wang, J. (2018) · Europe PMC (PubMed Central) · Cited by 38
Self-citation
Dietary berberine can ameliorate glucose metabolism disorder of Megalobrama amblycephala exposed to a high-carbohydrate diet
He, C., Jia, X., Zhang, L., Gao, F., Jiang, W., Wen, C., Chi, C., Li, X., Jiang, G., Mi, H., et al. (2021) · Fish Physiology and Biochemistry · doi:10.1007/s10695-021-00927-8 · Cited by 39
Self-citation
Study progress of berberine for treating cardiovascular disease
Xia, L., & Luo, M. (2015) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2015.11.006 · Cited by 39
“The BBR significantly reduced the total cholesterol by 29%, triglycerides by 35%, and LDL-C by 25%.(31) These results have been then confirmed in a larger trial carried out on 116 hyperlipidemic type 2 diabetic patients randomized to treatment with berberine 0.”
Result
Complementary and Alternative Medicine in Diabetes Care
DiNardo, M. M., Gibson, J. M., Siminerio, L. L., Morell, A. R., & Lee, E. S. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0315-2 · Cited by 37
The Efficacy and Safety of the Chinese Herbal Formula, JTTZ, for the Treatment of Type 2 Diabetes with Obesity and Hyperlipidemia: A Multicenter Randomized, Positive-Controlled, Open-Label Clinical Trial
Yu, X., Xu, L., Zhou, Q., Wu, S., Tian, J., Piao, C., Guo, H., Zhang, J., Li, L., Wu, S., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/9519231 · Cited by 39
“96mmol/L after 3 months of treatment [31].”
Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure
McCarty, M. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073321 · Cited by 41
Natural Bioactive Compounds as Potential Browning Agents in White Adipose Tissue
Choi, Y., & Yu, L. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03027-7 · Cited by 39
Berberine Regulated Gck, G6pc, Pck1 and Srebp-1c Expression and Activated AMP-activated Protein Kinase in Primary Rat Hepatocytes
Ge, Y., Zhang, Y., Li, R., Chen, W., Li, Y., & Chen, G. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.673 · Cited by 38
“The beneficial effects of berberine on type 2 diabetes and insulin resistance subjects (13-16) indicated that it may have effects on hepatocytes isolated from insulin resistant fatty rats.”
BackgroundInfluentialSelf-citation
Berberine inhibits Staphylococcus Epidermidis adhesion and biofilm formation on the surface of titanium alloy
Wang, X., Qiu, S., Xiao, Y., Tang, T., Dai, K., & Zhu, Z. (2009) · Journal of Orthopaedic Research® · doi:10.1002/jor.20917 · Cited by 37
“There is evidence that berberine, in addition to its antimicrobial effects, may also treat diabetes.(38,39) Accordingly, berberine appears to be a promising agent for the treatment of PPI in diabetic patients.”
Background
Inhibition of key enzymes linked to type 2 diabetes and sodium nitroprusside-induced lipid peroxidation in rat pancreas by water-extractable phytochemicals from unripe pawpaw fruit ( Carica papaya )
Oboh, G., Olabiyi, A. A., Akinyemi, A. J., & Ademiluyi, A. O. (2013) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2013-0002 · Cited by 37
“In vitro and in vivo studies have shown that natural plant alkaloid isolated from the Chinese herb, Coptis chinensis (Huanglian), has glucose-lowering effect and is also used in the treatment of diarrhea [58].”
Background
The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials
Xie, L., Zhang, D., Ma, H., He, H. R., Xia, Q., Shen, W., Chang, H., Deng, Y., Wu, Q., Cong, J., et al. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/7918631 · Cited by 38
Berberine, A Phytoalkaloid, Inhibits Inflammatory Response Induced by LPS through NF-Kappaβ Pathway: Possible Involvement of the IKKα
Reddi, K., Li, H., Li, W., & Tetali, S. (2021) · Molecules · doi:10.3390/molecules26164733 · Cited by 35
“Several clinical studies carried out with BBR have further supported its efficacy against chronic inflammatory diseases such as diabetes [14,15], hypertension [16,17], and hyperlipidemia [18,19].”
Background
Fermented Soybean Suppresses Visceral Fat Accumulation in Mice
Kushida, M., Okouchi, R., Iwagaki, Y., Asano, M., Du, M. X., Yamamoto, K., & Tsuduki, T. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201701054 · Cited by 35
Role of Gut Microbiota in the Pharmacological Effects of Natural Products
Pan, C., Qing-long, G., & Lu, N. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2682748 · Cited by 37
“Berberine, the main active ingredient of Chinese herb Coptis chinensis, is known as an antidiabetes drug and can regulate blood glucose [20, 21].”
Background
Bioactive dietary components—Anti‐obesity effects related to energy metabolism and inflammation
Silva, C. B., Zingg, J.-M. A., Fassini, P. G., & Suen, V. M. M. (2022) · BioFactors · doi:10.1002/biof.1921 · Cited by 35
“Berberine has also been described as having a thermogenic effect.(170,172,173) Zhang et al.”
Background
Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in Type 2 Diabetes Mellitus Treatment: A Review
Cortez-Navarrete, M., Pérez-Rubio, K. G., & Escobedo-Gutiérrez, M. D. J. (2023) · Pharmaceuticals · doi:10.3390/ph16040515 · Cited by 39
Tackling dipeptidyl peptidase IV in neurological disorders
Castorina, A., Al‐Badri, G., Leggio, G. M., Musumeci, G., Marzagalli, R., & Drago, F. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.224365 · Cited by 34
“Several studies have shown that human plasma levels after oral administration of relatively high doses of berberine barely reach the therapeutic window, whilst potentially triggering adverse gastrointestinal effects (Zhang et al., 2008; Hu et al., 2012).”
Background
Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial
Moon, J. M., Ratliff, K. M., Hagele, A. M., Stecker, R. A., Mumford, P. W., & Kerksick, C. M. (2021) · Nutrients · doi:10.3390/nu14010124 · Cited by 33
“[17] randomly assigned 116 individuals diagnosed with type 2 diabetes to consume two 500 mg daily doses (1000 mg total) over a 3-month period.”
Background
Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial
Li, Y., Ma, H., Zhang, Y., Kuang, H., Ng, E. H. Y., Hou, L., & Wu, X. (2013) · Trials · doi:10.1186/1745-6215-14-226 · Cited by 34
“Recently, berberine has been shown to have positive effects on type 2 diabetes mellitus, insulin resistance, lipid metabolism, nitric oxide production, and metabolic syndrome [10-13].”
BackgroundSelf-citation
Nutraceutical approaches to metabolic syndrome
Sirtori, C. R., Pavanello, C., Calabresi, L., & Ruscica, M. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1366042 · Cited by 35
Immune and Metabolic Regulation Mechanism of Dangguiliuhuang Decoction against Insulin Resistance and Hepatic Steatosis
Cao, H., Tuo, L., Tuo, Y., Xia, Z., Fu, R., Liu, Y., Quan, Y., Liu, J., Yu, Z., & Xiang, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00445 · Cited by 32
“The mechanisms of berberine in diabetes and inflammation include: regulating JNK and PPAR-α pathway, influencing transcriptional factors expression, such as PPAR-γ, C/EBP-α, SREBP-1c, LXR, and modulating IRS-1, Akt, and AMPK signal pathway (Zhang et al., 2008; Lou et al., 2011; Zhao et al., 2012; Deng and Xie, 2014).”
Background
Risk Associated with the Use of Selected Ingredients in Food Supplements
Jędrejko, K., Lazur, J., & Muszyńska, B. (2021) · Chemistry & Biodiversity · doi:10.1002/cbdv.202000686 · Cited by 32
“A meta-analysis conducted in 2012 showed that berberine use for 12 weeks in patients with diabetes improved all physiological markers of glucose and lipid levels.[147,148]”
Method
Ellagic Acid Stimulates Glucose Transport in Adipocytes and Muscles through AMPK Mediated Pathway
Poulose, N., Prasad, C. V., Haridas, P. A. N., & Gopalakrishnapillai, A. (2011) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000149 · Cited by 35
“Another example is berberine, an isoquinoline alkaloid that has gained substantial attention due to its blood glucose lowering effects in diabetic and insulin resistant states [15,16].”
Background
Application of Herbal Medicines with Bitter Flavor and Cold Property on Treating Diabetes Mellitus
Chen, H., Guo, J., Pang, B., Zhao, L., & Tong, X. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/529491 · Cited by 32
The Critical Role of mRNA Destabilizing Protein Heterogeneous Nuclear Ribonucleoprotein D in 3′ Untranslated Region–Mediated Decay of Low-Density Lipoprotein Receptor mRNA in Liver Tissue
Singh, A. B., Li, H., Kan, C. F. K., Dong, B., Nicolls, M. R., & Liu, J. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.301131 · Cited by 32
CURRENT TREATMENTS FOR TYPE 2 DIABETES, THEIR SIDE EFFECTS AND POSSIBLE COMPLEMENTARY TREATMENTS
Kalsi, A., Singh, S., Taneja, N., Kukal, S., & Mani, S. (2015) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 31
Berberine chloride improved synaptic plasticity in STZ induced diabetic rats
Moghaddam, H. K., Baluchnejadmojarad, T., Roghani, M., Goshadrou, F., & Ronaghi, A. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9411-5 · Cited by 31
Cardiotoxicity evaluation of nine alkaloids from Rhizoma Coptis
Zhang, M. Y., Yu, Y., Wang, S. F., Zhang, Q., Wu, H., Wei, J., Yang, W. M., Li, S., & Yang, H. (2017) · Human & Experimental Toxicology · doi:10.1177/0960327117695633 · Cited by 31
“Meanwhile, the clinical ADRs of berberine including constipation and other gastrointestinal reactions have been reported in recent years.(20,21) The toxicity of other alkaloids has been reported as well.”
Background
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Cicero, A. F. G. (2009) · Nutrition and Dietary Supplements · doi:10.2147/nds.s6084 · Cited by 31
“22 Moreover, the antihyperlipidemic effect of berberine was observed to be synergistic with other nutraceuticals inhibiting cholesterol synthesis such as monakolins and policosanols.”
Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial
Grant, S., Chang, D. H.-T., Liu, J., Wong, V., Kiat, H., & Bensoussan, A. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-104 · Cited by 31
“Firstly, our sample size may have lacked sufficient statistical power to detect a clinically significant change in FBG and to adequately account for the transient nature of people with IGT [19].”
BackgroundInfluential
Efficacy and safety of HIMABERB® berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
Panigrahi, A., & Mohanty, S. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01442-y · Cited by 30
“…the treatment of diabetes mellitus, Wei XC et al. [13] concluded that berberine significantly reduces glycemic control markers, including fasting plasma glucose, postprandial blood glucose, and HOMA-IR, in comparison to a control group of placebo or no intervention with medicine [14, 22, 25–29].”
Background
Evaluation of the C hinese herbal medicine J inlida in type 2 diabetes patients based on stratification: R esults of subgroup analysis from a 12‐week trial
Tian, J., Lian, F., Yang, L., & Tong, X. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12559 · Cited by 30
Adjunctive berberine reduces antipsychotic‐associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
Chan, M., Qin, Z., Man, S., Lam, M., Lai, W. H. E., Ng, R., Lee, C. K., Wong, T. L., Lee, E. H. M., Wong, H. K., et al. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13323 · Cited by 32
“0 kg of 3-month berberine treatment (1000 mg/d) in patients with diabetes.(25) A nearly 2-kg weight loss was achieved following 16 weeks of berberine treatment (1500 mg/d) in patients with nonalcoholic fatty liver disease.”
Background
Exploring the synergistic and complementary effects of berberine and paeoniflorin in the treatment of type 2 diabetes mellitus by network pharmacology
Zhang, L., Lin, H., Ma, J., Wu, T., Wei, Y., Zhao, L., & Tong, X. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174769 · Cited by 30
Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer
Yan, S., Hu, L.-M., Hao, X.-H., Liu, J., Tan, X., Geng, Z., Ma, J., & Wang, Z. (2022) · iScience · doi:10.1016/j.isci.2022.104773 · Cited by 30
Effect of ethanolic extract of Cryptolepis sanguinolenta stem on in vivo and in vitro glucose absorption and transport: Mechanism of its antidiabetic activity
Akhigbe, R. E., Ajayi, A. F., Adewumi, O. J., Okeleji, L., Mujaidu, K., & Olaleye, S. B. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94265 · Cited by 30
“They can activate AMPactivated protein kinase in 3T3-L1 adipocytes and L6 myotubes and facilitate GLUT4 translocation in L6 myotubes in a phosphatidylinositol 3-kinase-independent manner.[26] They have also been reported to promote glucose uptake in HepG2 and 3T3-L1 cells independent of insulin action.”
Background
Potential treatments for insulin resistance in the horse: A comparative multi-species review
Tinworth, K. D., Harris, P. A., Sillence, M. N., & Noble, G. K. (2009) · The Veterinary Journal · doi:10.1016/j.tvjl.2009.08.032 · Cited by 31
“in humans given 1 g/day of berberine for 3 months (Zhang et al., 2008).”
BackgroundInfluential
The Effects of Active Ingredients of Barberry Root (Berberine) on Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients
Rashidi, H., Namjoyan, F., Mehraban, Z., Zakerkish, M., Ghaderian, S. B., & Latifi, S. M. (2018) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp.64180 · Cited by 28
“In a study conducted by Yin et al., in Shanghai diabetes center, China, fasting blood glucose did not significantly decrease compared to the placebo group; however, postprandial blood glucose and Hb A1C significantly reduced (15).”
ResultInfluential
Development of an Innovative Berberine Food-Grade Formulation with an Ameliorated Absorption: In Vitro Evidence Confirmed by Healthy Human Volunteers Pharmacokinetic Study
Petrangolini, G., Corti, F., Ronchi, M., Arnoldi, L., Allegrini, P., & Riva, A. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/7563889 · Cited by 29
“&e potential usefulness of berberine in a variety of human diseases has been described bymany research papers: from type II diabetes [23, 24] due to berberine glucoselowering properties to metabolic syndrome and hyperlipemia [25, 26] and bacterial diseases due to the antimicrobial properties shown versus different mic…”
Background
AMPK activation—protean potential for boosting healthspan
McCarty, M. F. (2013) · AGE · doi:10.1007/s11357-013-9595-y · Cited by 30
Gut microbiota axis: potential target of phytochemicals from plant-based foods
Shi, R., Huang, C., Gao, Y., Li, X., Zhang, C., & Li, M. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.02.001 · Cited by 30
Self-citation
The effects of berberine supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis
Zamani, M., Zarei, M., Nikbaf-Shandiz, M., Hosseini, S., Shiraseb, F., & Asbaghi, O. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1013055 · Cited by 28
“A total of 14 effect sizes from 14 studies were included in the meta-analysis of the effect of BBR supplementation on HOMAIR (Figure 2H) (36, 38, 41, 44, 47, 48, 56, 58, 63, 67, 69, 72, 75, 78).”
BackgroundMethodInfluential
A Way Forward for Cancer Chemoprevention: Think Local
Rabadi, L. S. A., & Bergan, R. C. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0194 · Cited by 28
“5 g daily for 3 months has been found to be safe, and the herbal derivative is not considered toxic at these doses (165, 166).”
Background
Concentrated conservation and utilization: Four medicinal crops for diabetes treatment showed similar habitat distribution patterns in China
Cao, B., Bai, C., Wu, K., Xue, Y., Yang, H. J., Gao, P., Liang, H., & Li, G. (2020) · Industrial Crops and Products · doi:10.1016/j.indcrop.2020.112478 · Cited by 28
Lycopene Improves the Metformin Effects on Glycemic Control and Decreases Biomarkers of Glycoxidative Stress in Diabetic Rats
Figueiredo, I. D., Lima, T. F. O., Inácio, M. D., Costa, M. C., Assis, R. P., Brunetti, I. L., & Baviera, A. M. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s265944 · Cited by 30
Fructus Mume Formula in the Treatment of Type 2 Diabetes Mellitus: A Randomized Controlled Pilot Trial
Tu, X., Xie, C., Wang, F., Chen, Q., Zhihuang, Z., Zhang, Q., Wang, X., Zhong, S., & Jordan, J. B. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/787459 · Cited by 28
“In this pilot study, it was demonstrated that Fructus Mume formula may reduce the levels of blood glucose in patients with type 2 diabetes.”
Background
A Single Arm Pilot Study of Effects of Berberine on the Menstrual Pattern, Ovulation Rate, Hormonal and Metabolic Profiles in Anovulatory Chinese Women with Polycystic Ovary Syndrome
Li, L., Li, C., Pan, P., Chen, X., Wu, X., Ng, E. H. Y., & Yang, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144072 · Cited by 30
“5g twice times daily for 3 months and found plasma glucose, TG, TC and LDL-C decreased significantly compared to placebo [15].”
Background
Berberine attenuates high glucose-induced fibrosis by activating the G protein-coupled bile acid receptor TGR5 and repressing the S1P2/MAPK signaling pathway in glomerular mesangial cells
Yang, Z., Li, J., Xiong, F., Huang, J., Chen, C., Liu, P., & Huang, H. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.06.005 · Cited by 28
Plant-derived natural agents as dietary supplements for the regulation of glycosylated hemoglobin: A review of clinical trials
Rezaeiamiri, E., Bahramsoltani, R., & Rahimi, R. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.02.006 · Cited by 28
Feeding brown fat: dietary phytochemicals targeting non-shivering thermogenesis to control body weight
Horváth, C., & Wolfrum, C. (2020) · Proceedings of The Nutrition Society · doi:10.1017/s0029665120006928 · Cited by 29
“BBR was equally effective in placebocontrolled trials with Chinese type 2 diabetic and dyslipidaemic patients (1 g daily)((207)) or poor glycaemic control (1⋅5 g daily)((208)).”
Background
Antidiabetic effect of nepodin, a component of Rumex roots, and its modes of action in vitro and in vivo
Ha, B. G., Yonezawa, T., Son, M. J., Woo, J. T., Ohba, S., Chung, U., & Yagasaki, K. (2014) · BioFactors · doi:10.1002/biof.1165 · Cited by 27
Berberine attenuates high glucose-induced proliferation and extracellular matrix accumulation in mesangial cells: Involvement of suppression of cell cycle progression and NF-κB/AP-1 pathways
Lan, T., Wu, T., Chen, C., Chen, X., Hao, J., Huang, J., Wang, L., & Huang, H. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.01.022 · Cited by 27
Berberine acutely inhibits the digestion of maltose in the intestine
Li, Z., Zuo, D., Qie, X.-D., Qi, H., Zhao, M., & Wu, Y. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.05.022 · Cited by 27
“…of the rhizome of coptis (Tang et al., 2006), which is the Chinese Goldthread Rhizome for medicinal using, and berberine administered orally has a similar hypoglycemic activity to the Chinese Goldthread Rhizome in clinical (Ni, 1988; Yin et al., 2008b; Zhang et al., 2008; Zhang et al., 2010).”
Background
Structural modification of berberine alkaloid and their hypoglycemic activity
Ding, Y., Ye, X., Zhu, J., Zhu, X., Li, X., & Chen, B. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.02.007 · Cited by 27
Self-citation
Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice
Li, M., Dang, Y., Li, Q., Zhou, W., Zuo, J., Yao, Z., Zhang, L. R., & Ji, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-44576-7 · Cited by 27
Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review
Araj‐Khodaei, M., Ayati, M. H., Azizi-Zeinalhajlou, A., Novinbahador, T., Yousefi, M., Shiri, M., Mahmoodpoor, A., Shamekh, A., Namazi, N., & Sanaie, S. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2023.2258559 · Cited by 30
“BBR is also a regulatory factor in lipid and glucose metabolism that reduces insulin resistance in both humans and animals (Zhang et al .”
A thorough analysis of diabetes research in China from 1995 to 2015: current scenario and future scope
Wu, Z., Jin, T., & Weng, J. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9377-y · Cited by 27
Randomised clinical trial of Berberis vulgaris root extract on glycemic and lipid parameters in type 2 diabetes mellitus patients
Tahmasebi, L., Zakerkish, M., Golfakhrabadi, F., & Namjoyan, F. (2019) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2019.100998 · Cited by 26
Effects of berberine and barberry on anthropometric measures: A systematic review and meta-analysis of randomized controlled trials
Amini, M. R., Sheikhhossein, F., Naghshi, S., Djafari, F., Askari, M., Shahinfar, H., Safabakhsh, M., Jafari, A., & Shab‐Bidar, S. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102337 · Cited by 27
Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia
Chou, W.-L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105693 · Cited by 30
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus
He, Q., Dong, H., Guo, Y., Gong, M., Xia, Q., Lu, F., & Wang, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1074348 · Cited by 27
Semen Cassiae Extract Improves Glucose Metabolism by Promoting GlUT4 Translocation in the Skeletal Muscle of Diabetic Rats
Zhang, M., Li, X., Liang, H., Cai, H., Hu, X., Bian, Y., Dong, L., Ding, L., Wang, L., Yu, B., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00235 · Cited by 26
Self-citation
Effectiveness of traditional Chinese medicine Jinlida granules as an add‐on therapy for type 2 diabetes: A system review and meta‐analysis of randomized controlled trials
Lian, F., Jin, D., Bao, Q. D., Zhao, Y. C., & Tong, X. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12877 · Cited by 25
Berberine alleviates palmitic acid‑induced podocyte apoptosis by reducing reactive oxygen species‑mediated endoplasmic reticulum stress
Xiang, X.-Y., Liu, T., Wu, Y., Jiang, X.-S., He, J., Chen, X., & Du, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11641 · Cited by 25
“numerous studies have assessed the effects of BBr on hyperglycemia and dyslipidemia (17,34).”
Background
Effect of Berberis vulgaris L. root extract on ifosfamide-induced in vivo toxicity and in vitro cytotoxicity
Ilyas, S., Tabasum, R., Iftikhar, A., Nazir, M., Hussain, A., Hussain, A., Ali, M. S., Saleem, F., Saleem, U., Froeyen, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80579-5 · Cited by 25
Activation of Insulin Signaling by Botanical Products
Rosenzweig, T., & Sampson, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084193 · Cited by 25
The protective effect of berberine on β-cell lipoapoptosis
Gao, N., Zhao, T.-Y., & Li, X. J. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03347042 · Cited by 25
Self-citation
Preventive use of berberine in inhibition of lead-induced renal injury in rats
Hasanein, P., & Riahi, H. (2017) · Environmental Science and Pollution Research · doi:10.1007/s11356-017-0702-y · Cited by 25
Dai-Zong-Fang, A Traditional Chinese Herbal Formula, Ameliorates Insulin Resistance in db/db Mice
Zhu, L., Zhu, X., Sun, G., Meng, X., Wang, M., Cui, H., Wang, J., Zhai, Y., Yang, K., Tang, Y., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00224 · Cited by 25
“As a main component of DZF, berberine has the hypoglycemic, hypolipidemic, and insulin sensitizing effect (Yin et al., 2008; Zhang et al., 2008; Wang et al., 2011; Pirillo and Catapano, 2015), attenuating hepatic steatosis (Sun et al.”
BackgroundSelf-citation

Authors: Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., Ren, G., & Ning, G.
Affiliations: Shanghai Jiao Tong University (CN)
Second Military Medical University (CN)
Department of Endocrinology (J.Y., G.R.), Min-Hang Hospital, Shanghai 201100, People’s Republic of China
Corresponding author: Ning, Guang
ORCID: Zhang, Yifei
Liu, Wei
Yang, Jialin
Zhu, Na
Wang, Miao
Hong, Jie
Ning, Guang
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2008-07-01
Volume: 93
Issue: 7
Pages: 2559-2565
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2007-2404
OpenAlex: W1969395627
Cited by: 573
References: 23
Citations by year: 2026: 30 · 2025: 27 · 2024: 28 · 2023: 33 · 2022: 41 · 2021: 54 · 2020: 46 · 2019: 42 · 2018: 33 · 2017: 23 · 2016: 29 · 2015: 32 · 2014: 34 · 2013: 31 · 2012: 25
FWCI: 14.72
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: berberine, type 2 diabetes, dyslipidemia, glucose-lowering effect, insulin sensitivity, glucose disposal rate, hyperinsulinemic-euglycemic clamp, HbA1c, serum lipids, triglycerides, LDL cholesterol, total cholesterol, plant alkaloids, constipation, drug safety, antidiabetic therapy, lipid-lowering therapy
MeSH terms: Adult, Aged, Berberine, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks